This post was originally published on this site

BidaskClub cut shares of Fulcrum Therapeutics (NASDAQ:FULC) from a buy rating to a hold rating in a report issued on Thursday morning, BidAskClub reports.

FULC has been the topic of several other reports. Zacks Investment Research cut Fulcrum Therapeutics from a buy rating to a hold rating in a report on Wednesday, November 11th. Piper Sandler started coverage on Fulcrum Therapeutics in a report on Thursday, October 15th. They issued an overweight rating and a $22.00 target price on the stock. Finally, SVB Leerink reduced their target price on Fulcrum Therapeutics from $25.00 to $23.00 and set an outperform rating on the stock in a report on Tuesday, November 10th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $17.43.

NASDAQ:FULC opened at $11.71 on Thursday. The stock has a market cap of $321.59 million, a P/E ratio of -4.07 and a beta of 0.96. The stock’s 50-day moving average is $12.15 and its 200-day moving average is $12.15. Fulcrum Therapeutics has a 1-year low of $7.01 and a 1-year high of $22.96.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.70) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.66) by ($0.04). The firm had revenue of $1.85 million during the quarter, compared to the consensus estimate of $2.00 million. Equities analysts forecast that Fulcrum Therapeutics will post -2.77 earnings per share for the current fiscal year.

Institutional investors have recently bought and sold shares of the business. Point72 Asset Management L.P. bought a new position in shares of Fulcrum Therapeutics during the 2nd quarter worth approximately $4,768,000. FMR LLC boosted its holdings in shares of Fulcrum Therapeutics by 3.8% during the 2nd quarter. FMR LLC now owns 1,850,552 shares of the company’s stock worth $33,847,000 after buying an additional 68,101 shares in the last quarter. New York State Common Retirement Fund boosted its holdings in shares of Fulcrum Therapeutics by 112.7% during the 2nd quarter. New York State Common Retirement Fund now owns 12,267 shares of the company’s stock worth $224,000 after buying an additional 6,500 shares in the last quarter. American International Group Inc. boosted its holdings in shares of Fulcrum Therapeutics by 11.9% during the 3rd quarter. American International Group Inc. now owns 8,557 shares of the company’s stock worth $68,000 after buying an additional 907 shares in the last quarter. Finally, Nuveen Asset Management LLC boosted its holdings in shares of Fulcrum Therapeutics by 37.8% during the 2nd quarter. Nuveen Asset Management LLC now owns 49,362 shares of the company’s stock worth $902,000 after buying an additional 13,532 shares in the last quarter. Hedge funds and other institutional investors own 71.25% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and Ã-thalassemia.

Featured Story: Most Active Stocks

Receive News & Ratings for Fulcrum Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Fulcrum Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.